OrthoPediatrics Corp. (NASDAQ:KIDS) Expected to Announce Quarterly Sales of $22.70 Million

Wall Street brokerages forecast that OrthoPediatrics Corp. (NASDAQ:KIDSGet Rating) will report $22.70 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for OrthoPediatrics’ earnings. The highest sales estimate is $23.00 million and the lowest is $22.45 million. OrthoPediatrics reported sales of $21.46 million in the same quarter last year, which would suggest a positive year over year growth rate of 5.8%. The firm is scheduled to issue its next earnings report on Monday, January 1st.

On average, analysts expect that OrthoPediatrics will report full year sales of $119.16 million for the current fiscal year, with estimates ranging from $118.04 million to $119.93 million. For the next financial year, analysts anticipate that the firm will post sales of $142.85 million, with estimates ranging from $141.38 million to $143.80 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for OrthoPediatrics.

OrthoPediatrics (NASDAQ:KIDSGet Rating) last posted its quarterly earnings data on Wednesday, March 2nd. The company reported ($0.24) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.05. OrthoPediatrics had a negative net margin of 16.58% and a negative return on equity of 6.54%. During the same quarter in the previous year, the company posted ($0.31) EPS.

KIDS has been the subject of a number of recent research reports. Truist Financial lowered their price target on shares of OrthoPediatrics from $78.00 to $75.00 and set a “buy” rating for the company in a research report on Tuesday, December 21st. TheStreet upgraded shares of OrthoPediatrics from a “d+” rating to a “c” rating in a research report on Monday, April 4th. BTIG Research cut their target price on shares of OrthoPediatrics from $75.00 to $68.00 and set a “buy” rating for the company in a research report on Wednesday, December 22nd. Finally, Needham & Company LLC dropped their price target on shares of OrthoPediatrics from $83.00 to $65.00 and set a “buy” rating for the company in a research report on Thursday, March 3rd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $73.67.

Shares of OrthoPediatrics stock opened at $48.75 on Wednesday. The firm has a market cap of $962.81 million, a PE ratio of -58.04 and a beta of 0.79. OrthoPediatrics has a 12-month low of $43.09 and a 12-month high of $73.91. The company’s fifty day simple moving average is $51.81 and its two-hundred day simple moving average is $56.44.

In other news, SVP Joseph W. Hauser sold 3,220 shares of the company’s stock in a transaction dated Monday, February 7th. The shares were sold at an average price of $46.04, for a total value of $148,248.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Mark C. Throdahl sold 5,961 shares of the company’s stock in a transaction dated Wednesday, March 2nd. The stock was sold at an average price of $58.60, for a total transaction of $349,314.60. The disclosure for this sale can be found here. Insiders sold 26,204 shares of company stock worth $1,482,701 in the last three months. Insiders own 30.30% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the business. Riverbridge Partners LLC raised its position in shares of OrthoPediatrics by 3.2% in the 4th quarter. Riverbridge Partners LLC now owns 1,105,273 shares of the company’s stock valued at $66,162,000 after purchasing an additional 34,358 shares during the last quarter. Wasatch Advisors Inc. grew its stake in OrthoPediatrics by 0.9% in the 4th quarter. Wasatch Advisors Inc. now owns 499,437 shares of the company’s stock valued at $29,896,000 after acquiring an additional 4,503 shares during the period. Summit Partners Public Asset Management LLC grew its stake in OrthoPediatrics by 11.5% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 436,123 shares of the company’s stock valued at $26,106,000 after acquiring an additional 44,973 shares during the period. Invesco Ltd. lifted its holdings in OrthoPediatrics by 3.4% in the 3rd quarter. Invesco Ltd. now owns 425,727 shares of the company’s stock valued at $27,889,000 after purchasing an additional 13,965 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its holdings in OrthoPediatrics by 2.5% in the 4th quarter. New York State Common Retirement Fund now owns 383,879 shares of the company’s stock valued at $22,979,000 after purchasing an additional 9,437 shares in the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

About OrthoPediatrics (Get Rating)

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

Featured Articles

Get a free copy of the Zacks research report on OrthoPediatrics (KIDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.